{"schema_version":"secwatch.filing_event.v1","accession":"0001770787-23-000006","form_type":"8-K","ticker":"TXG","cik":"0001770787","company_name":"10x Genomics, Inc.","filed_at":"2023-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.481079+00:00","generated_at":"2026-06-19T11:47:45.580759+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"10x Genomics Q4 revenue up 9% to $156.2M; FY net loss triples to $166M, guides FY23 rev $580-600M","bullets":["Q4 2022 revenue $156.2M (+9% YoY); FY 2022 revenue $516.4M (+5% YoY).","Gross margin fell to 76% in Q4 (from 81%) and 77% for FY (from 85%) due to product mix.","Operating loss widened to $23.1M in Q4 and $167.9M for FY, driven by higher stock-based compensation.","Net loss for FY 2022 was $166.0M vs $58.2M in 2021; cash + securities $430M.","FY 2023 revenue guidance $580M-$600M (12-16% growth); began shipping Xenium in situ platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001770787-23-000006","json":"https://secwatch.observer/filing/0001770787-23-000006.json","markdown":"https://secwatch.observer/filing/0001770787-23-000006.md","text":"https://secwatch.observer/filing/0001770787-23-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770787/000177078723000006/0001770787-23-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770787/000177078723000006/txg-20230215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T11:47:45.580759+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3306cceb04c192d5b9d6254abe79e52de393ef32","claim":"10x Genomics, Inc. reported fourth quarter and full year ended December 31, 2022 results: revenue $156.2 million for the fourth quarter and $516.4 million for the full year, net income Net loss was $17.2 million for the fourth quarter...Net loss was $166.0 million for full year 2022. Guidance initiated.","evidence_excerpt":"Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided outlook for 2023. Recent Highlights • Revenue was $156.2 million for the fourth quarter and $516.4 million for the full year of 2022, representing 9% and 5% increases over the corresponding periods of 2021. • Increased cumulative instruments","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770787/000177078723000006/0001770787-23-000006-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2022"},{"label":"Revenue","value":"$156.2 million for the fourth quarter and $516.4 million for the full year"},{"label":"Net income","value":"Net loss was $17.2 million for the fourth quarter...Net loss was $166.0 million for full year 2022"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}